UPPSALA, SWEDEN / ACCESS Newswire / March 5, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The Board of Directors of Biovica International AB today announces that Chief Executiv ...
KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, su ...
UroGen Pharma's ZUSDURI is positioned for accelerated adoption following a permanent J-Code in 2026. Read more on URGN stock and why it is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results